Proteolysis-targeting chimeras and their implications in breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Breast cancer (BC) is a significant global health concern, with ERα+ and HER2+ subtypes comprising the majority of cases.
• Current targeted therapies for ERα+ and HER2+ BC are effective but face challenges due to acquired resistance.
• There is a critical need for innovative therapeutic strategies to improve patient outcomes.

Purpose of the Study:

• To explore the potential of Proteolysis-Targeting Chimeras (PROTACs) as a novel therapeutic modality for breast cancer.
• To discuss the application of PROTACs in targeting key drivers of ERα-positive and HER2-positive breast cancer.
• To highlight the mechanism of action of PROTACs in protein degradation for cancer therapy.

Main Methods:

• Review of current literature on breast cancer subtypes and targeted therapies.
• Explanation of the molecular structure and mechanism of PROTACs.
• Discussion of PROTACs' potential in overcoming therapeutic resistance in ERα+ and HER2+ BC.

Main Results:

• PROTACs are bifunctional molecules designed to induce targeted protein degradation.
• PROTACs offer a promising approach to overcome resistance mechanisms observed with conventional therapies.
• The modular nature of PROTACs allows for tailored drug design against specific targets in breast cancer.

Conclusions:

• PROTACs represent a promising new class of therapeutics for managing ERα-positive and HER2-positive breast cancer.
• Targeted protein degradation via PROTACs offers a potential strategy to overcome treatment resistance.
• Further research and development of PROTACs could lead to improved treatment outcomes for breast cancer patients.